Treatment of Edoxaban Versus Aspirin for Non-disabling Cerebrovascular Events: Rationale, Objectives, and Design
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 3,700
- 试验地点
- 1
- 主要终点
- percentage of patients with new stroke (ischemic or hemorrhage)
研究概览
简要总结
Transient ischemic attack (TIA) or minor ischemic stroke has a high risk of early recurrent stroke. As the golden standard, aspirin effect modestly on acute ischemic stroke, and slightly increase the risk of intracerebral hemorrhage. Recently, edoxaban, a new oral anticoagulant, is proved to be as effective as traditional anticoagulants, while carrying significantly less risk of intracranial hemorrhage.
This trial is a randomized, double-blind, multicenter, controlled clinical trial in China. The investigators will assess the hypothesis that a 30-days edoxaban regimen is superior to aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult subjects (male or female ≥18 years old)
- •Acute nondisabling ischemic stroke (NIHSS ≤3 at the time of randomization) that can be treated with study drug within 24 hours of symptoms onset. Symptom onset is defined by the "last see normal" principle
- •TIA (neurologic deficit attributed to focal brain ischemia, with resolution of the deficit within 24 hours of symptom onset), that can be treated with investigational medication within 24 hours of symptoms onset. Symptom onset is defined by the "last see normal" principle
- •Informed consent signed
排除标准
- •Diagnosis of hemorrhage or other pathology, such as vascular malformation, tumor, abscess or other major nonischemic brain disease, on baseline head CT or MRI scan
- •mRS score >2 at randomization (premorbid historical assessment)
- •NIHSS ≥4 at randomization
- •Clear indication for anticoagulation (atrial fibrillation, mechanical cardiac valves, deep venous thrombosis, pulmonary embolism or known hypercoagulable state)
- •Contraindication to investigational medications
- •Thrombolysis for ischemic stroke within preceding 7 days
- •History of intracranial hemorrhage
- •Current treatment (last dose given within 10 days before randomization) with heparin therapy or oral anticoagulation
- •Gastrointestinal bleed or major surgery within 3 months
- •Planned or likely revascularization (any angioplasty or vascular surgery) within the next 3 months
- •TIA or minor stroke induced by angiography or surgery
- •Severe noncardiovascular comorbidity with life expectancy <3 months
- •Women of childbearing age not practicing reliable contraception who do not have a documented negative pregnancy test result
- •Severe renal failure, defined as Glomerular Filtration Rate (GFR) <30 ml/min -Severe hepatic insufficiency (Child-Pugh score B to C)
研究组 & 干预措施
aspirin
Receiving a 100-mg dose of aspirin and placebo edoxaban from day 1 to day 30
干预措施: Aspirin (Drug)
aspirin
Receiving a 100-mg dose of aspirin and placebo edoxaban from day 1 to day 30
干预措施: placebo (Drug)
edoxaban 30mg
Receiving a 30-mg dose of edoxaban and placebo aspirin from day 1 to day 30
干预措施: edoxaban (Drug)
edoxaban 30mg
Receiving a 30-mg dose of edoxaban and placebo aspirin from day 1 to day 30
干预措施: placebo (Drug)
edoxaban 60mg
Receiving a 60-mg dose of edoxaban and placebo aspirin from day 1 to day 30
干预措施: edoxaban (Drug)
edoxaban 60mg
Receiving a 60-mg dose of edoxaban and placebo aspirin from day 1 to day 30
干预措施: placebo (Drug)
结局指标
主要结局
percentage of patients with new stroke (ischemic or hemorrhage)
时间窗: 90 days
次要结局
- Percentage of patients with new clinical vascular events (ischemic stroke/hemorrhagic stroke/TIA/myocardial infarction/vascular death)(30 days)
- moderate to severe bleeding events(90 days)
- Adverse events/severe adverse events reported by the investigators(90 days)
- mRS score changes (continuous) and dichotomized at percentage with score 0 to 2 versus 3 to 6(30 days and 90 days)
- Changes in NIHSS scores(90 days)
- Total mortality(90 days)